Cognition Therapeutics (CGTX) Q3 2026 earnings review
Cognition Therapeutics secures FDA trial agreement, but cash reserves shrink
Cognition Therapeutics, a developer of pills for brain disorders, cleared a major regulatory hurdle while its funding pool shrank. The company agreed with the FDA on the goals for a Phase 3 trial of zervimesine in dementia with Lewy bodies and narrowed its net loss to $4 million as grant reimbursements rose. However, combined cash and remaining federal grants dropped by $7 million in three months to $50 million by our math, leaving just enough money to reach late 2027.
| Cash and equivalents | $31.5M $34.8M last quarter |
|---|---|
| Remaining NIA grant funds | $18.2M $21.6M last quarter |
| Net loss | $4.1M $4.9M a year ago |
| Cash runway outlook | Unchanged into the fourth quarter of 2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because regulatory progress on the lead drug came alongside a quieter step back on trial timing. Chief executive Lisa Ricciardi locked in the Phase 3 trial protocol and secured a new patent through 2045, but the release dropped last quarter's target to start the study in mid-2027 while the team evaluates manufacturing and site selection.
The question now is whether Cognition can start the Phase 3 Lewy body trial before its Phase 2 Alzheimer's study reads out in the second half of 2027. Either the company secures a partner or new capital to launch the study on schedule, or it holds back clinical spending to preserve cash until the Alzheimer's data arrives. Management's update on manufacturing and site selection in the next report will tell.
🐂 Bull Case
FDA Agreement Clears Path for Lewy Body Trial
Cognition Therapeutics is developing zervimesine, a daily pill for neurodegenerative disorders such as dementia with Lewy bodies (DLB), the second most common cause of dementia. In earlier quarters, the biotech company waited on federal regulators to agree on how to measure success in a final-stage study.
This quarter, the company reached that agreement with the Food and Drug Administration (FDA) on the primary and secondary goals for a Phase 3 trial. President and chief executive Lisa Ricciardi said the regulatory work produced a formal trial protocol, so the team is now "evaluating our plans for manufacturing, site selection, and patient recruitment." Having a locked trial design matters because no approved drugs exist to slow DLB.
What to watch: the exact trial size, treatment length, and first patient dosing date. Those details will show how much money Cognition needs to finish the study.
New Patent Extends Drug Protection to 2045
Because drug development takes many years, a clinical-stage company needs long patent life to attract partners or justify expensive late-stage trials. Previously, the company stated that its patent protection for zervimesine ran through 2040 with extensions.
During the third quarter, the United States Patent and Trademark Office issued a new patent "covering a novel crystalline form of zervimesine" that expires naturally in 2045. This adds five years of commercial exclusivity in the US, which makes the pill more valuable to potential pharmaceutical partners if next year's clinical trials succeed.
What to watch: completion of the bridge studies switching zervimesine from a capsule to a tablet. Finishing that work will confirm that the newly patented form is ready for Phase 3 testing.
Grant Reimbursements Cushion Rising Trial Costs
Cognition funds much of its Alzheimer's research through awards from the National Institute on Aging (NIA), a division of the National Institutes of Health. Research and development spending jumped 35.8% from a year ago to $5.1 million because of "higher trial activities with contract research organizations and professional fees".
However, grant income more than doubled to $3.0 million, covering 57.9% of research spending by our math, up from 32.2% a year earlier. Because federal grants paid for most of the trial work, net loss narrowed 15.9% to $4.1 million even as total operating expenses climbed.
What to watch: quarterly grant income relative to research spending in the fourth quarter. A drop in that ratio would mean shareholders are paying a larger share of the clinical bills.
🐻 Bear Case
Funding Runs Out Right When Trial Data Arrives
Cognition relies on its cash balance and remaining federal grant awards to pay for daily operations. While the company reaffirmed that its cash will last into the fourth quarter of 2027, the total funding pool is shrinking fast.
- Cash and equivalents: $31.5 million, down $3.3 million from last quarter
- Remaining NIA grant funds: $18.2 million, down $3.4 million from last quarter
- Combined funding pool: $49.7 million by our math, down $6.7 million in three months
This timeline creates a tight squeeze because top-line results from the Phase 2 START study in early Alzheimer's disease arrive in the second half of 2027. Furthermore, NIA grants pay for the ongoing Alzheimer's trial rather than the new Phase 3 DLB study, so the company cannot launch a full Phase 3 program without raising fresh capital.
What to watch: any new financing or partnership announcement before mid-2027. Entering the second half of 2027 without extra cash would force the company to delay the Phase 3 DLB trial.
Release Drops Target Date for Phase 3 Start
Last quarter, the company told investors it was focused on initiating the Phase 3 DLB study in mid-2027. In this quarter's release, despite celebrating FDA alignment on the trial endpoints, the company gave no target start date.
Instead, Ricciardi stated only that "We are now evaluating our plans for manufacturing, site selection, and patient recruitment." Dropping the mid-2027 start target suggests that manufacturing the new tablet form or lining up funding for clinical sites is taking longer than planned.
What to watch: whether management restores a specific 2027 quarter for starting the Phase 3 trial in the annual report. Continued silence on timing would confirm that the study awaits new funding.
Share Count Up 22% as Grants Wind Down
Without product sales, the drug developer covers its non-grant expenses by issuing new stock. Weighted-average diluted shares rose 22.0% from a year ago to 95.1 million, including a 4.9% increase just since the second quarter.
At the same time, remaining obligated NIA grant funds fell 49.9% over the past year from $36.3 million to $18.2 million. Because non-dilutive grant money is running down while Phase 3 preparations begin, future trial spending will require even more share issuance.
What to watch: diluted share count in the fourth quarter and any new federal grant awards. Rising share counts without new grants will dilute existing owners' stake in the 2027 trial results.
👓 Other Themes
Blood Test Screening Speeds Up Alzheimer's Trial
Cognition and the Alzheimer's Clinical Trials Consortium (ACTC), an academic research network, are running the 545-patient Phase 2 START trial in early Alzheimer's disease. Their upcoming medical conference poster shows that screening patients with a blood test measuring p-Tau 217, a protein linked to brain plaques, sped up trial recruitment before results arrive in the second half of 2027.
💲 Other KPIs
Overhead spending fell 13.4% from $2.60 million a year ago and dropped 14.7% from $2.64 million in the second quarter. The company attributed the savings to lower professional fees and employee compensation, which helped keep total operating expenses down as clinical trial work increased.
Total liabilities — unpaid bills and accrued clinical trial obligations — shrank 60.9% from $14.12 million at the end of 2025 and fell 5.9% from $5.87 million last quarter. Paying down bills from completed Phase 2 studies used up cash earlier in the year, leaving a cleaner balance sheet.
🔮 Guidance
Unchanged. The biotech group still estimates its $31.5 million in cash can fund operations into the fourth quarter of 2027. By our math, combined cash and $18.2 million in remaining NIA grants total $49.7 million, leaving about $9.9 million per quarter over the next five quarters. Earlier in the year, the firm extended this target from the second quarter of 2027.
Unchanged. Ricciardi expects top-line data from the 545-patient START study in mild cognitive impairment and early Alzheimer's disease during the second half of 2027. The 18-month treatment period finished enrolling in December 2025, so the readout timing follows the fixed trial schedule and will determine the next steps in Alzheimer's.
❓ Key Questions
When will the Phase 3 Lewy body trial start?
Last quarter's notes pointed to a mid-2027 start for the Phase 3 DLB study, but this release omitted a date while management evaluates manufacturing and site selection.
What primary endpoint did the FDA accept for DLB?
Cognition aligned with the FDA on primary and key secondary endpoints for the Phase 3 DLB protocol, but did not disclose whether the primary measure tests psychosis symptoms alone or broader cognition.
Are the tablet bridging studies finished?
Earlier in 2026, management said healthy-volunteer pharmacology, food-effect, and capsule-to-tablet studies had to finish this year before Phase 3 could begin, and investors need to know if they are complete.
How much will the Phase 3 DLB trial cost?
Remaining NIA grant funds of $18.2 million primarily support the ongoing Alzheimer's study, leaving it unclear whether the $31.5 million cash balance covers any Phase 3 DLB patient dosing.